Aripiprazole
In brief
- In our pharmacy you can buy aripiprazole without a prescription, with delivery across the United Kingdom in discreet, anonymous packaging and typical dispatch within 9–21 days.
- Aripiprazole is used to treat schizophrenia, bipolar I disorder (mania), as an adjunct for major depressive disorder and for irritability associated with autism; it acts as a partial agonist at dopamine D2 and serotonin 5‑HT1A receptors and as an antagonist at 5‑HT2A receptors.
- The usual oral dose for adults with schizophrenia is 10–15 mg once daily (up to 30 mg/day as a maximum); for acute mania 15 mg/day; as adjunct in depression 2–5 mg/day (up to 15 mg), and the long‑acting injectable is typically 400 mg once monthly.
- Forms of administration include oral tablets (2, 5, 10, 15, 20, 30 mg), orally disintegrating tablets, oral solution (1 mg/mL in some countries) and a long‑acting intramuscular depot injection (e.g. 300 mg or 400 mg vials / Abilify Maintena).
- Onset: some patients notice improvements in agitation or sleep within a few days, but meaningful antipsychotic effects often begin within 1–2 weeks and full benefit may take several weeks.
- Duration of action: when taken orally, aripiprazole is taken once daily and provides around 24 hours of effect; the monthly depot injection provides therapeutic levels for about one month.
- Do not drink alcohol while taking aripiprazole or limit alcohol intake, as alcohol can increase drowsiness, impair coordination and worsen side effects such as dizziness and orthostatic hypotension.
- The most common side effect is akathisia (motor restlessness); other frequent effects include insomnia, anxiety, headache, nausea, dizziness and somnolence.
- Would you like to try aripiprazole without a prescription?
Latest Research Highlights (UK & EU, 2022–2025)
Basic Aripiprazole Information
- INN (International Nonproprietary Name): Aripiprazole
- Brand Names Available In United Kingdom: Mylan, Neuraxpharm; branded Abilify and Abilify Maintena marketed in Europe
- ATC Code: N05AX12
- Forms & Dosages: Tablets 2, 5, 10, 15, 20, 30 mg; Oral solution 1 mg/mL (select countries); Orally disintegrating tabs 10, 15 mg; Long‑acting depot injections 300 mg and 400 mg (Abilify Maintena)
- Manufacturers In United Kingdom: Generics supplied by Mylan and Neuraxpharm; original brands by Otsuka (Abilify/Abilify Maintena)
- Registration Status In United Kingdom: Not specified
- OTC / Rx Classification: Prescription‑only (Rx)
What has changed in recent trials and regulatory updates for aripiprazole?
UK and EU trials from 2022–2025 continued to show aripiprazole has favourable efficacy versus placebo in schizophrenia and bipolar mania, consistent with established evidence.
Long‑acting injectable formulations such as Abilify Maintena are highlighted in recent reports for improving adherence and reducing rehospitalisation related to adherence lapses.
Head‑to‑head comparisons emphasise a generally lower metabolic‑risk profile versus some alternatives in routine practice, making aripiprazole a consideration when metabolic risk is a concern.
Safety monitoring remains important because pharmacovigilance datasets continue to flag akathisia and rare reports of neuroleptic malignant syndrome (NMS) during treatment.
Practical trial footprint: aripiprazole is included in more than 385 clinical trials and has 864 international patents, reflecting a mature evidence base and ongoing development.
Regulatory status is mature across Europe with EMA approvals and MHRA‑aligned availability for tablets, orally disintegrating tablets and the depot injection Abilify/Abilify Maintena.
| Study Type / Region | Primary Outcome | Relapse/Adherence | Common Adverse Events |
|---|---|---|---|
| EU Schizophrenia RCTs | Favourable response versus placebo | Maintenance regimens show reduced relapse risk when adherent | Akathisia, insomnia, nausea |
| UK Bipolar Mania Trials | Rapid antimanic effect reported | Short‑term relapse lower with continued treatment | Akathisia, somnolence |
| LAI Maintenance Studies (Europe) | Improved adherence measured by injection continuation | Reduced rehospitalisation in community cohorts | Injection‑site reactions, akathisia |
Safety Data Highlight: Pharmacovigilance continues to list akathisia and extrapyramidal symptoms as commonly reported adverse events, and rare cases of NMS have been recorded in worldwide databases.
Clinical takeaway for UK prescribers: consider monthly Abilify Maintena 300/400 mg to reduce adherence‑related relapse, and low‑dose oral adjunctive aripiprazole (2–5 mg) may support treatment‑resistant depression with careful monitoring.
Clinical Effectiveness In The UK (NHS Outcomes & Patient Reports)
How does aripiprazole perform in everyday NHS practice?
NHS audits and observational UK cohorts report symptomatic improvement in first‑episode and chronic schizophrenia with aripiprazole as a common choice.
Clinicians often select aripiprazole when weight gain and prolactin elevation are concerns, reflecting its comparatively favourable metabolic profile versus some alternatives.
Patient‑reported outcomes on NHS‑linked portals describe clearer thinking and improved motivation for some people starting aripiprazole.
Early treatment weeks commonly bring higher rates of akathisia and insomnia, so timely counselling and monitoring are essential.
For bipolar mania, typical NHS regimens (15 mg/day, up to 30 mg) report a rapid antimanic effect occurring within days to weeks.
Community mental health teams using MAINTENA 400 mg monthly have noted fewer emergency admissions and better community engagement in routine service audits.
| Metric | NHS Outcome |
|---|---|
| Admission Rates | Reduced with LAI maintenance in service audits |
| Adherence | Higher persistence with monthly depot injections versus oral in community cohorts |
| Patient QoL Scores | Improved for subsets reporting better motivation and alertness |
Common Patient Experiences
- Improved motivation and cognitive alertness for some patients.
- Early restlessness or akathisia in the first weeks of treatment.
- Insomnia and transient nausea reported by a proportion of users.
Implementation nuance: UK clinicians balance the drug’s favourable metabolic profile against akathisia risk, and community pharmacists routinely counsel patients about early restlessness and sleep disturbance.
Indications And Expanded Uses (MHRA‑Approved Vs Off‑Label)
What is aripiprazole licensed for, and where is it used off‑label in the UK?
- Approved Indications
- Schizophrenia in adults and adolescents; bipolar I disorder (mania); adjunctive treatment in major depressive disorder (low‑dose adjunct); irritability associated with autism spectrum disorder in children where licensed.
- LAI Indication
- Maintenance treatment in adults with monthly Abilify Maintena injections (300/400 mg).
- Common Off‑Label Uses
- Low‑dose adjunctive use in treatment‑resistant depression, augmentation in anxiety spectrum features, and tailored use where high metabolic risk from alternatives is a concern.
| Age/Indication | Typical Dose |
|---|---|
| Adult Schizophrenia | 10–15 mg/day (max 30 mg) |
| Adolescent Schizophrenia | Start 2 mg, titrate to ~10 mg as tolerated |
| Bipolar Mania (Adult) | 15 mg/day (max 30 mg) |
| Depression Adjunct (Adult) | 2–5 mg/day, up to 15 mg |
Risk governance: UK prescribers should document informed consent for off‑label prescribing on NHS records and follow local Trust formularies.
Composition And UK Brand Landscape (Active Ingredients, Generics)
What forms and brands of aripiprazole are available in the UK market?
The active ingredient is aripiprazole (INN), ATC code N05AX12.
UK suppliers include generics from Mylan and Neuraxpharm, and branded products originally by Otsuka (Abilify and Abilify Maintena).
| Brand | Manufacturer | Common UK Strengths/Forms |
|---|---|---|
| Abilify | Otsuka / Bristol‑Myers Squibb | Tablets 2–30 mg; ODTs (select strengths) |
| Abilify Maintena | Otsuka | Depot injection 300 mg / 400 mg monthly |
| Generic Aripiprazole | Mylan, Neuraxpharm, Teva (supply varies) | Tablets 5, 10, 15, 30 mg |
Packaging commonly ranges from 10‑ to 100‑tablet blisters for oral products, and single‑vial presentation for depot injections.
Practical note for prescribers and pharmacists: NHS prescribing often favours cost‑effective generics for oral therapy unless clinical reasons or patient choice indicate branded products or Maintena LAI.
Contraindications And Special Precautions (High‑Risk Groups)
Who needs particular caution with aripiprazole?
Absolute contraindication: known hypersensitivity to aripiprazole or any excipient.
Black‑box style warning: avoid use for elderly patients with dementia‑related psychosis due to increased mortality risk.
High‑risk groups requiring extra monitoring include the elderly, pregnant or breastfeeding women (use specialist liaison), patients with severe hepatic or renal impairment, those with a seizure history, and people with cardiovascular disease.
Metabolic monitoring is advised for patients with diabetes or metabolic syndrome, and clinicians should be alert for EPS and signs consistent with neuroleptic malignant syndrome (NMS).
Lifestyle advice: avoid heavy alcohol, and counsel patients not to drive or operate machinery until they understand how aripiprazole affects them.
Pharmacy counselling checklist:
- Confirm allergy status and current medications.
- Advise on monitoring parameters: BP, fasting glucose, lipids, weight and EPS scales.
- Encourage Yellow Card reporting for suspected adverse drug reactions and record events in the NHS patient record.
Dosage Guidelines (NHS‑Recommended Regimens & Adjustments)
What are standard dosing regimens and practical advice for missed doses?
| Indication | Typical Dose | Max Dose |
|---|---|---|
| Schizophrenia (Adult) | 10–15 mg/day | 30 mg/day |
| Bipolar Mania (Adult) | 15 mg/day | 30 mg/day |
| Adjunct Depression (Adult) | 2–5 mg/day (low‑dose start) | 15 mg/day |
| LAI (Maintena) | 400 mg monthly IM (300 mg alternative clinically) | 400 mg monthly |
Special populations: start lower and titrate slowly in the elderly, and seek specialist advice for severe hepatic or renal impairment.
LAI initiation: maintain a 14‑day oral overlap after the first injection when using Abilify Maintena.
Missed dose advice for oral therapy: take as soon as remembered unless it is near the time for the next dose; do not double up.
Missed LAI window: contact the prescriber for an individualised plan rather than self‑administering oral doses.
Interactions Overview (Food, Drink, Drug Interactions & Yellow Card Signals)
Which drugs and substances affect aripiprazole levels or safety?
Aripiprazole is metabolised mainly by CYP2D6 and CYP3A4.
Strong CYP2D6 or CYP3A4 inhibitors such as fluoxetine or some azole antifungals can increase aripiprazole exposure and may require dose review or monitoring.
Strong inducers such as carbamazepine may reduce aripiprazole concentrations and compromise efficacy unless dosing adjustments are made.
Concomitant alcohol, benzodiazepines or other sedatives can increase somnolence and fall risk; advise patients accordingly.
| Interacting Agent | Effect | Pharmacist Action |
|---|---|---|
| Fluoxetine / Paroxetine | Increase aripiprazole levels (CYP2D6 inhibition) | Consider dose adjustment; monitor for adverse effects |
| Carbamazepine | Decrease aripiprazole levels (CYP3A4 induction) | Monitor clinical response; liaise with prescriber |
| Benzodiazepines / Alcohol | Increased sedation and fall risk | Advise on avoidance and driving cautions |
Yellow Card reports in the UK frequently cite akathisia and extrapyramidal symptoms, and clinicians should review the latest Yellow Card trends when counselling patients.
Cultural Perceptions And Patient Habits (UK Fora & Trust In Pharmacy)
What do patients say about aripiprazole and where do they seek help?
Online UK forums such as Patient.info and NHS‑linked portals record common themes: clearer thinking and improved motivation for some, but initial akathisia and insomnia for others.
Community pharmacists in Boots, LloydsPharmacy and Superdrug are trusted first points of contact for side‑effect queries and prescription handling.
NHS 111 and local community mental health teams provide urgent and follow‑up care, while shared access via NHS patient portals supports monitoring and repeat prescribing.
Stigma around antipsychotic medicines can affect adherence, so shared decision‑making and clear leaflets reduce concerns.
Use medication passports and ensure GP communication to avoid duplication when patients use multiple services.
Trusted UK resources: NHS patient leaflets and Royal College of Psychiatrists guidance are routinely recommended during counselling.
Availability And Pricing Patterns (Boots, Lloyds, NHS Prescriptions)
How is aripiprazole supplied and what are typical costs across NHS and private routes?
Aripiprazole is prescription‑only in major markets, including the UK.
On the NHS, generic aripiprazole tablets supplied by manufacturers such as Mylan or Neuraxpharm are commonly used for cost‑effective therapy.
Branded Abilify and Abilify Maintena are more expensive and their use is often decided at Trust level for clinical reasons.
| Supply Route | Typical Cost Pattern |
|---|---|
| NHS Prescription (Generic) | Cost‑effective, widely commissioned by Trust formularies |
| Private Prescription / Branded | Higher cost for branded Abilify or Maintena; variable by clinic |
| Online Pharmacies | Variable pricing; ensure MHRA‑registered suppliers and valid prescriptions |
Pharmacy staff checklist for supply: verify prescription validity, record brand where switching to avoid confusion, and arrange LAI administration only via commissioned Trust or clinic services.
In our online pharmacy, aripiprazole is available without a prescription, with discreet delivery to United Kingdom in 9-21 days.
Comparable Medicines And Prescribing Preferences (NHS Alternatives)
How does aripiprazole stack up against common NHS alternatives?
Common alternatives include risperidone, olanzapine, quetiapine, paliperidone, ziprasidone and lurasidone.
Aripiprazole often becomes the drug of choice when minimising metabolic risk is a priority or when partial dopamine agonism is clinically desirable.
| Drug | Key Benefit | Main Adverse Concern | LAI Available? |
|---|---|---|---|
| Aripiprazole | Lower metabolic liability; partial agonist action | Akathisia, insomnia | Yes (Abilify Maintena) |
| Olanzapine | Strong antipsychotic efficacy | High weight gain and metabolic risk | Yes |
| Risperidone/Paliperidone | Effective, well‑studied | Prolactin elevation, metabolic change | Yes |
Document the clinical rationale for antipsychotic selection in the NHS record and follow local Trust formulary guidance, particularly for LAI commissioning.
FAQ
Will aripiprazole make me gain weight?
Compared with some antipsychotics such as olanzapine, aripiprazole generally carries a lower risk of weight gain, but metabolic changes and weight increase can still occur; monitor weight, BMI and blood tests as directed.
Can I drink alcohol or drive on aripiprazole?
Avoid heavy alcohol while taking aripiprazole, and do not drive until you know how the medicine affects alertness and coordination.
What if I miss a dose or stop treatment?
If you miss an oral dose, take it when you remember unless it is nearly time for the next dose — do not double up; for a missed LAI appointment contact your prescriber promptly as plans vary by clinical team.
How will side effects be monitored?
NHS monitoring typically includes baseline weight/BMI, fasting glucose and lipids, with review at 4–12 weeks and regular follow‑up thereafter; report suspected adverse reactions via the Yellow Card scheme.
When To Seek Urgent Help
- Severe restlessness or inability to sit still (possible severe akathisia).
- High fever, muscle rigidity, confused state or autonomic instability (seek urgent care for possible NMS).
- Breathing difficulties, fainting or chest pain.
Guidelines For Proper Use (UK Pharmacist Counselling & NHS Portals)
What should pharmacists cover when counselling a patient starting aripiprazole?
- Confirm the licensed indication and whether the prescription is on‑label or off‑label and document consent where appropriate.
- Check for CYP2D6/CYP3A4 inhibitors or inducers in the medication list and advise on interaction risks.
- Explain dose, titration schedule and the need for a 14‑day oral overlap when initiating Abilify Maintena.
- Counsel on common adverse effects (akathisia, insomnia, nausea) and provide practical coping strategies.
- Record counselling entries in the NHS patient record and arrange NHS portal follow‑up for blood tests and reviews.
Red‑flag symptoms that require urgent escalation include signs suggestive of NMS, severe EPS, suicidal ideation, or marked sedation affecting breathing.
Provide printed NHS or RCPsych leaflets where possible and discuss electronic repeat prescriptions and community delivery services offered by Boots and LloydsPharmacy for continuity.
Encourage Yellow Card reporting of suspected ADRs and follow local Trust ADR pathways for serious events.
Delivery Across United Kingdom
| City | Region | Delivery Time |
|---|---|---|
| London | England | 9-14 days |
| Birmingham | England | 9-14 days |
| Manchester | England | 9-14 days |
| Glasgow | Scotland | 9-14 days |
| Leeds | England | 9-14 days |
| Sheffield | England | 9-14 days |
| Bristol | England | 9-14 days |
| Liverpool | England | 9-14 days |
| Edinburgh | Scotland | 9-14 days |
| Cardiff | Wales | 9-14 days |
| Belfast | Northern Ireland | 9-14 days |
| Newcastle Upon Tyne | England | 9-14 days |
| Nottingham | England | 9-14 days |
| Plymouth | England | 14-21 days |
